About Us

We believe our passion can lead to real change for patients, and our approach goes beyond what’s expected

Leading the way to a potential new standard of care for acid-related gastrointestinal (GI) disorders.

Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, an investigational potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders. Vonoprazan has the potential to be the first gastric anti-secretory agent from a new class approved in the United States, Europe, or Canada in over 30 years.

We released topline results from two Phase 3 clinical trials for the treatment of H. pylori infection and erosive GERD. The company has also initiated a Phase 2 trial to evaluate various doses of vonoprazan as an on-demand therapy for patients with nonerosive reflux disease (NERD).

Management Team

Meet our team of experts working to usher in a new era of treatment for patients with acid-related disorders.

terrie curran

Terrie Curran

President & Chief Executive Officer

azmi nabulsi

Azmi Nabulsi, M.D., M.P.H.

Chief Operating Officer

phathom edit headshot5 010320 v01

Martin Gilligan

Chief Commercial Officer

joe hand

Joe Hand, J.D.

Chief Administrative Officer

tom harris

Tom Harris

Head of Regulatory Affairs

eckhard leifke

Eckhard Leifke, M.D., Ph.D.

Chief Medical Officer

larry miller

Larry Miller, J.D.

General Counsel

Board of Directors

Terrie Curran

Terrie Curran

President & Chief Executive Officer, Phathom

David Socks

David Socks

Chief Financial Officer & Chief Business Officer, HilleVax, Inc.

michaelcola newbg

Michael Cola

Chief Executive Officer, Avalo Therapeutics, Inc.

Heidi Kunz

Heidi Kunz

Former Chief Financial Officer, Blue Shield California

Asit Parikh

Asit Parikh, M.D., Ph.D.

President & Chief Executive Officer, MOMA Therapeutics

david socks

Mark Stenhouse

Chief Operating Officer, Prometheus Biosciences

Phathom Co-Founders

Tachi Yamada

Tadataka (Tachi) Yamada, M.D.

Co-Founder and Late Chairman, Phathom

David Socks

David Socks

Co-Founder, Phathom

azmi nabulsi

Azmi Nabulsi, M.D., M.P.H.

Co-Founder, Phathom

aditya kohli

Aditya Kohli, Ph.D.

Co-Founder, Phathom